ANI Pharmaceuticals
ANIP
126 hedge funds and large institutions have $259M invested in ANI Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 21 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 44
0.27% less ownership
Funds ownership: 53.6% → 53.33% (-0.27%)
5% less funds holding
Funds holding: 132 → 126 (-6)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
37% less capital invested
Capital invested by funds: $413M → $259M (-$154M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
66% less call options, than puts
Call options by funds: $707K | Put options by funds: $2.09M
Top Buyers
Top Sellers
ANIP Hedge Fund Activity: Q1 2022 in Review
126 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2022, worth a combined $259M — down 37% from $413M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANIP and 17 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 52 added.
The largest buyer was Emerald Advisers, adding an estimated $10.1M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $14.2M sold.
- 126 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2022, down from 132 in Q4 2021.
- Funds reported $259M of ANI Pharmaceuticals stock for Q1 2022, down 37% quarter-over-quarter.
- 17 funds opened new ANI Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of -4 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2022 was Emerald Advisers, an estimated $10.1M added.
- The largest ANI Pharmaceuticals seller in Q1 2022 was Rubric Capital Management (New York), an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2022.